About CTI Cancer Research, Cancer Therapies, and Cancer Drug Development

We believe in leveraging the intellectual, financial, and commercial strengths of strategic corporate partnerships to bring the full potential of our product candidates to market.

We also believe in the value of strategic timing. Before seeking development or commercialization partners, we develop our products through mid- to late-stage clinical development. As a result, we are best positioned to assess and realize their full value. Ultimately, this strategy will allow us to choose the best partner on more favorable terms than might be available if we entered into collaborative relationships during earlier stages of product development.

Systems Medicine

Additional collaborations came to CTI with our acquisition of Systems Medicine in July 2007, including:

Nerviano Medical Sciences, Milan
The largest pharmaceutical research and development facility in Italy and one of the largest oncology-focused, integrated discovery and development companies in Europe.

The Translational Genomics Research Institute (TGen)
A biomedical research institute that makes and translates genomic discoveries into advances in health.

The Cancer Drug Development Laboratory
A robotics-intensive division of TGen applying advanced genomic technologies (e.g., RNA interference) to translational drug development.

TGen Drug Development Services
An oncology-focused CRO providing preclinical evaluation of the safety and efficacy of a drug using the most relevant animal models and genomic analyses.

Molecular Profiling Institute
A specialty reference laboratory that helps cancer patients worldwide by applying the discoveries of the Human Genome Project to personalized medicine.

CPath Institute
An Arizona based non-profit organization focused on enabling the accelerated development of new medications founded by FDA, the University of Arizona, and SRI International.

Novartis

In September 2006, we entered into an exclusive worldwide licensing agreement with Novartis for the development and commercialization of OPAXIO™ (paclitaxel poliglumex; formerly branded as XYOTAX). The agreement also provides Novartis with an option to develop and commercialize pixantrone based on agreed terms. Novartis agreed to make a $15 million equity investment in CTI.

PG-TXL Company, L.P.

In June 1998, we entered into an agreement with PG-TXL Company, L.P. granting us an exclusive worldwide license for the rights to PG-TXL, known as XYOTAX™, and to all potential uses of PG-TXL's polymer technology.

Under the terms of the agreement, we will fund the research, development, manufacture, marketing, and sale of anti-cancer drugs developed using PG-TXL's polymer technology. We are obligated to make payments upon the attainment of significant development milestones, as defined in the agreement.